

Please use this form if you want the Hong Kong Offer Shares to be issued in your name
如閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

This Application Form uses the same terms as defined in the prospectus of Shenzhen Heparlink Pharmaceutical Group Co., Ltd. (the “Company”) dated June 24, 2020 (the “Prospectus”).

本申請表格所使用詞彙與深圳市海普瑞藥業集團股份有限公司(「本公司」)於2020年6月24日刊發的招股章程(「招股章程」)所界定詞彙相同。

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.

本申請表格及招股章程概不構成在香港以外任何司法管轄區的出售要約或游說購買任何香港發售股份的要約。若無根據美國《證券法》登記或豁免登記，則香港發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.

在任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法管轄區內，概不得發送、派發或複製(不論以任何方式，也不論全部或部分)本申請表格及招股章程。

Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection — Documents Delivered to the Registrar of Companies in Hong Kong” section in Appendix VII to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), Hong Kong Securities Clearing Company Limited (“HKSCC”), the Securities and Futures Commission of Hong Kong (the “SFC”) and the Registrar of Companies in Hong Kong take no responsibility for the contents of these documents.

招股章程、所有相關申請表格及招股章程附錄七「送呈香港公司註冊處處長及備查文件 — 送呈香港公司註冊處處長文件」一節所述其他文件已遵照香港法例第32章《公司(清盤及雜項條文)條例》第342C條的規定，送呈香港公司註冊處處長登記。香港交易及結算有限公司、香港聯合交易所有限公司(「香港聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對此等文件的內容概不負責。



海普瑞

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

Stock code : 9989

股份代號 : 9989

**Minimum Offer Price : HK\$20.60 per H Share, plus brokerage of 1.0%,
SFC transaction levy of 0.0027% and Hong Kong**

Stocking Fee 0.5% (S)0.5% (o)0.5%

Please use this form if you want the Hong Kong Offer Shares to be issued in your name

如閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

Signed by (all) applicant(s) (all joint applicants must sign):
由(所有)申請人簽署(所有聯名申請人必須簽署):

Date: 日期:
D 日 M 月 Y 年

Number of Hong Kong Offer Shares applied for (not more than 11,005,000 H Shares)
申請香港發售股份數目(不超過11,005,000股H股)

--

Total amount 總額

HK\$		港元
------	--	----

Name in English in BLOCK letter 英文姓名 名稱(英文 高煌 S 焉@誅步

For Broker use 此欄供經紀填寫 Lodged by 遞交申請的經紀

Broker No. 經紀號碼

Broker's Chop 經紀印章

--	--	--	--	--	--	--	--

Cheque/banker's cashier order number 支票 銀行本票號碼

--

Name of bank on which cheque/banker's cashier order is drawn
(see "How to make your application" section) 兌現支票 銀行本票的銀行名稱(見「申請手續」一節)

--

Please use this form if you want the Hong Kong Offer Shares to be issued in your name
如閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

- * (1) An individual must provide his Hong Kong Identity Card number or, if he does not hold a Hong Kong Identity Card, his passport number. A body corporate must provide its Hong Kong Business Registration number. Each joint applicant must provide its or his relevant number. The Hong Kong Identity Card number(s)/passport number(s)/Hong Kong Business Registration number(s) will be transferred to a third party for checking the Application Form's validity.
個別人士須填寫其香港身份證號碼或(如非香港身份證持有人)護照號碼。法人團體須填寫其香港商業登記號碼。每名聯名申請人均須提供其相關號碼。該等香港身份證號碼護照號碼香港商業登記號碼將轉交第三方以核實申請表格是否有效。
- (2) Part of the Hong Kong Identity Card number/passport number of you or, for joint applicants, the first-named applicant may be printed on your refund cheque (if any). Your banker may require verification of your Hong Kong Identity Card number/passport number before you can cash your refund cheque.
退款支票(如有)上或會印有閣下或(如屬聯名申請人)排名首位申請人的香港身份證號碼護照號碼的一部分。銀行兌現退款支票前或會要求查證閣下的香港身份證號碼護照號碼。
- (3) If an application is made by an unlisted company and:
• the principal business of that company is dealing in securities; and
• you exercise statutory control over that company,
then the application will be treated as being made for your benefit.
倘若申請人是一家非上市公司，而：
• 該公司主要從事證券買賣業務；及
• 閣下對該公司可行使法定控制權，
是項申請將視作為閣下的利益提出。

樣版

This page is intentionally left blank
此乃白頁 特意留空

Sample

Please use this form if you want the Hong Kong Offer Shares to be issued in your name

How to make your application

- Use the table below to calculate how much you must pay. Your application must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.

NUMBER OF HONG KONG OFFER SHARES THAT MAY BE APPLIED FOR AND PAYMENTS							
No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application
	HK\$		HK\$		HK\$		HK\$
500	10,403.80	10,000	208,075.86	200,000	4,161,517.24	7,000,000	145,653,103.40
1,000	20,807.59	15,000	312,113.79	300,000	6,242,275.86	8,000,000	166,460,689.60
1,500	31,211.38	20,000	416,151.72	400,000	8,323,034.48	9,000,000	187,268,275.80
2,000	41,615.17	25,000	520,189.66	500,000	10,403,793.10	10,000,000	208,075,862.00
2,500	52,018.97	30,000	624,227.59	600,000	12,484,551.72	11,005,000 ⁽¹⁾	228,987,486.13
3,000	62,422.76	35,000	728,265.52	700,000	14,565,310.34		
3,500	72,826.56	40,000	832,303.45	800,000	16,646,068.96		
4,000	83,230.34	45,000	936,341.38	900,000	18,726,827.58		
4,500	93,634.14	50,000	1,040,379.31	1,000,000	20,807,586.20		
5,000	104,037.93	60,000	1,248,455.17	2,000,000	41,615,172.40		
6,000	124,845.52	70,000	1,456,531.03	3,000,000	62,422,758.60		
7,000	145,653.10	80,000	1,664,606.90	4,000,000	83,230,344.80		
8,000	166,460.69	90,000	1,872,682.76	5,000,000	104,037,931.00		
9,000	187,268.28	100,000	2,080,758.62	6,000,000	124,845,517.20		

(1) Maximum number of Hong Kong Offer Shares you may apply for.

- Complete the form in English in BLOCK letter and sign it. Only written signatures will be accepted (and not by way of personal chop).
- Staple your cheque or banker's cashier order to the form. Each application for the Hong Kong Offer Shares must be accompanied by either one separate cheque or one separate banker's cashier order. Your application will be rejected if your cheque or banker's cashier order does not meet all the following requirements:

The cheque must:	Banker's cashier order must:
<ul style="list-style-type: none"> be in Hong Kong dollars; not be post-dated; be made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED SHENZHEN HEPALINK PHARMACEUTICAL PUBLIC OFFER"; be crossed "Account Payee Only"; 	<ul style="list-style-type: none"> be issued by a licensed bank in Hong Kong, and have your name cer T* [(I)0.5 (f (e)0.5 (b)0.0. I it is a joint appl5cation, tur sam, Ioe aRe muse25nm witm we sm
<ul style="list-style-type: none"> be drawn on your Hong Kong dollar bank account in Hong Kong; and show your account name, which must either be pre-printed on the cheque, or be endorsed on the back by a person authorised by the bank. This account name must correspond with your name. If it is a joint application, the account name must be the same as the first-named applicant's name. 	

Please use this form if you want the Hong Kong Offer Shares to be issued in your name

4. Tear off the Application Form, fold it once and lodge your completed Application Form (with cheque or banker's cashier order attached) to one of the collection boxes at any of the following branches of the following receiving banks:

Bank of China (Hong Kong) Limited

District	Branch Name	Address
Hong Kong Island	Bank of China Tower Branch	1 Garden Road, Hong Kong
Kowloon	Kwun Tong Plaza Branch	G1 Kwun Tong Plaza, 68 Hoi Yuen Road, Kwun Tong, Kowloon
	Yau Ma Tei Branch	471 Nathan Road, Yau Ma Tei, Kowloon
New Territories	Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan O, New Territories
	Yuen Long Branch	102–108 Castle Peak Road, Yuen Long, New Territories
	Castle Peak Road (Tsuen Wan) Branch	G/F–1/F, Sin Ching Building, 201–207 Castle Peak Road (Tsuen Wan), Tsuen Wan, New Territories

- 5.

如閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

申請手續

1. 使用下表計算閣下應付的款項。閣下申請認購的股數須至少為500股香港發售股份，並為下表所列的其中一個數目，否則恕不受理。

可供申請認購香港發售股份數目及應繳款項							
申請認購的 香港發售 股份數目	申請時 應繳款項	申請認購的 香港發售 股份數目	申請時 應繳款項	申請認購的 香港發售 股份數目	申請時 應繳款項	申請認購的 香港發售 股份數目	申請時 應繳款項
	港元		港元		港元		港元
500	10,403.80	10,000	208,075.86	200,000	4,161,517.24	7,000,000	145,653,103.40
1,000	20,807.59	15,000	312,113.79	300,000	6,242,275.86	8,000,000	166,460,689.60
1,500	31,211.38	20,000	416,151.72	400,000	8,323,034.48	9,000,000	187,268,275.80
2,000	41,615.17	25,000	520,189.66	500,000	10,403,793.10	10,000,000	208,075,862.00
2,500	52,018.97	30,000	624,227.59	600,000	12,484,551.72	11,005,000 ⁽¹⁾	228,987,486.13
3,000	62,422.76	35,000	728,265.52	700,000	14,565,310.34		
3,500	72,826.56	40,000	832,303.45	800,000	16,646,068.96		
4,000	83,230.34	45,000	936,341.38	900,000	18,726,827.58		
4,500	93,634.14	50,000	1,040,379.31	1,000,000	20,807,586.20		
5,000	104,037.93	60,000	1,248,455.17	2,000,000	41,615,172.40		
6,000	124,845.52	70,000	1,456,531.03	3,000,000	62,422,758.60		
7,000	145,653.10	80,000	1,664,606.90	4,000,000	83,230,344.80		
8,000	166,460.69	90,000	1,872,682.76	5,000,000	104,037,931.00		
9,000	187,268.28	100,000	2,080,758.62	6,000,000	124,845,517.20		

(1) 閣下可申請認購的香港發售股份最高數目。

2. 以英文正楷填妥及簽署表格。只接納親筆簽名(不得以個人印章代替)。
3. 閣下須將支票或銀行本票釘於表格上。每份香港發售股份申請須附一張獨立開出支票或一張獨立開出銀行本票。支票或銀行本票必須符合以下所有規定，否則有關認購申請將不獲接納：

支票必須：	銀行本票必須：
<ul style="list-style-type: none"> • 為港元開出； • 不得為期票； • 註明抬頭人為「中國銀行(香港)代理人有限公司—深圳市海普瑞藥業公開發售」； • 劃線註明「只准入抬頭人賬戶」； 	<ul style="list-style-type: none"> • 須由香港持牌銀行開出，並由有關銀行授權的人士在銀行本票背面簽署核證閣下姓名名稱。銀行本票所示姓名名稱須與閣下姓名名稱相同。如屬聯名申請，銀行本票背面所示姓名名稱必須與排名首位申請人的姓名名稱相同。
<ul style="list-style-type: none"> • 從閣下在香港的港元銀行賬戶中開出；及 • 顯示閣下的賬戶名稱，而該賬戶名稱必須已預印在支票上，或由有關銀行授權的人士在支票背書。賬戶名稱必須與閣下姓名名稱相同。如屬聯名申請，則賬戶名稱必須與排名首位申請人的姓名名稱相同。 	

如閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

4. 請撕下申請表格，對摺一次，然後將填妥的申請表格(連同隨附的支票或銀行本票)投入下列收款銀行的任何一家分行特設的收集箱：

中國銀行(香港)有限公司

地區	分行名稱	地址
香港島	中銀大廈分行	香港花園道1號
九龍	觀塘廣場分行	九龍觀塘開源道68



Hepalink

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Conditions of your application

A. Who can apply

1. You and any person(s) for whose benefit you are applying must be 18 years of age or older and must have a Hong Kong address.
2. If you are a firm, the application must be in the individual members' names.
3. The number of joint applicants may not exceed 4.
4. If you are a body corporate, the application must be signed by a duly authorised officer, who must state his representative capacity, and stamped with your corporation's chop.

5. You must be a resident of the Hong Kong Special Administrative Region of the People's Republic of China.

ueusdw -1.236 -c(u)0.52-8 7 -a (s)0.5 (i)0.5 (d)6.5 (i)0.5w (s)0.1 Td [(d)0.5 (5 (u)0.5 (u)0. (P)0.5 (e)0.5 (r)0.5 (s)0.5 (i)0.55 (p)0. (s)0.5 (r)0.5 (e)0.5 (u)0.i (e)0.n (e)0.5 (r)0. (

Please use this form if you want the Hong Kong Offer Shares to be issued in your name

- declare and represent that this is the only application made and the only application intended by you to be made to benefit you or the person for whose benefit you are applying;
- understand that the Company and the Joint Global Coordinators will rely on your declarations and representations in deciding whether or not to make any allotment of any of the Hong Kong Offer Shares to you and that you may be prosecuted for making a false declaration;
- (if the application is made for your own benefit) warrant that no other application has been or will be made for your benefit on a **WHITE** or **YELLOW** Application Form or by giving electronic application instructions to HKSCC or to the **HK eIPO White Form** Service Provider by you or by any one as your agent or by any other person; and
- (if you are making the application as an agent for the benefit of another person) warrant that (i) no other application has been or will be made by you as an agent for or for the benefit of that person or by that person or by any other person as an agent for that person on a **WHITE** or **YELLOW** Application Form or by giving electronic application instructions to HKSCC; and (ii) you have due authority to sign the Application Form or give electronic application instructions on behalf of that other person as their agent.

D. Power of attorney

If your application is made through an authorised attorney, the Company and the Joint Global Coordinators may accept or reject your application at their discretion, and on any conditions they think fit, including evidence of the attorney's authority.

Determination of Offer Price and Allocation of Hong Kong Offer Shares

The Offer Price is expected to be fixed on or around Tuesday, June 30 2020. Applicants are required to pay the maximum Offer Price of HK\$20.60 for each Hong Kong Offer Share together with 1% brokerage, 0.0027% SFC transaction levy and 0.005% Hong Kong Stock Exchange trading fee. If the Offer Price is not agreed between the Company and the Joint Global Coordinators (for themselves and on behalf of the Underwriters) on or before Thursday, July 2 2020, the Global Offering will not proceed.

Applications for Hong Kong Offer Shares will not be processed and no allotment of any Hong Kong Offer Shares will be made until the application lists close.

The Company expects to announce the final Offer Price, the indication of the level of interest in the International Offering, the level of applications under the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares under the Hong Kong Public Offering on Tuesday, July 7 2020 on the website of the Hong Kong Stock Exchange at www.hkexnews.hk and the Company's website at www.hepalink.com



海普瑞

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(於中華人民共和國註冊成立的股份有限公司)

全球發售

申請條件

甲、可提出申請的人士

- 閣下及閣下為其利益提出申請的人士必須年滿18歲並有香港地址。
- 如閣下為商號，則申請須以個別成員名義提出。
- 聯名申請人不得超過四名。
- 如閣下為法人團體，申請須獲正式授權人員簽署，並註明其所代表身份及蓋上公司印鑑。
- 閣下必須身處美國境外，並非美籍人士(定義見美國《證券法》S規例)又或屬美國《證券法》S規例第902條第(h)(3)段所述的人士，亦非中國法人或自然人。
- 除《上市規則》或香港聯交所已授予的任何相關豁免批准外，下列人士概不得申請認購任何香港發售股份：
 - 本公司及 或其任何附屬公司股份的現有實益擁有人；
 - 本公司及 或其任何附屬公司的董事或行政總裁；
 - 上述任何人士的緊密聯繫人；
 - 本公司核心關連人士或緊隨全球發售完成後成為本公司核心關連人士的人士；或
 - 已獲分配或已申請或表示有意申請任何國際發售股份或以其他方式參與國際發售的人士。

乙、如閣下為代名人

閣下作為代名人可提出超過一次香港發售股份申請，方法是：(i)透過中央結算及交收系統(「中央結算系統」)向香港結算發出電子認購指示(如閣下為中央結算系統參與者)；或(ii)使用白色或黃色申請表格，以自身名義代表不同的實益擁有人提交超過一份申請。

丙、填交本申請表格的效用

閣下填妥並遞交本申請表格，即表示閣下(如屬聯名申請人，即各人共同及個別)代表閣下本身，或作為閣下代其行事的每位人士的代理或代名人：

- 承諾簽立所有相關文件，並指示及授權本公司及 或作為本公司代理的聯席全球協調人(或彼等的代理或代名人)，代表閣下簽立任何文件，並按照公司章程的規定代表閣下辦理一切必要事宜以將閣下獲分配的任何香港發售股份以閣下名義登記；
- 同意遵守香港法例第622章《公司條例》、香港法例第32章《公司(清盤及雜項條文)條例》、中國《公司法》及公司章程；
- 確認閣下已細閱招股章程及本申請表格所載的條款及條件以及申請程序，並同意受其約束；
- 確認閣下已接獲及細閱招股章程，提出申請時也僅依據招股章程載列的資料及陳述，且除招股章程任何補充文件所載者外，不會依賴任何其他資料或陳述；

- 確認閣下知悉招股章程內有關全球發售的限制；
- 同意本公司、聯席保薦人、聯席全球協調人、承銷商、彼等各自的董事、高級人員、僱員、合夥人、代理、顧問及參與全球發售的任何其他人士現時及日後均毋須對並非載於招股章程(及其任何補充文件)的任何資料及陳述負責；
- 承諾及確認閣下或閣下為其利益提出申請的人士並無申請或接納或表示有意認購(亦不會申請或接納或表示有意認購)國際發售的任何國際發售股份，亦無參與國際發售；
- 同意在本公司、H股證券登記處、收款銀行、聯席保薦人、聯席全球協調人、承銷商及 或彼等各自的顧問及代理提出要求時，向彼等披露其所要求提供有關閣下及閣下為其利益提出申請人士的個人資料；
- 若香港境外任何地方的法例適用於閣下的申請，則同意及保證閣下已遵守所有有關法例，且本公司、聯席保薦人、聯席全球協調人及承銷商或彼等各自的任何高級人員或顧問概不會因接納閣下的購買要約，或閣下在招股章程及本申請表格所載條款及條件項下的權利及責任所引致的任何行動，而違反香港境外的任何法例；
- 同意閣下的申請一經接納，即不得因無意的失實陳述而撤銷；
- 同意閣下的申請受香港法例規管；
- 聲明、保證及承諾：(i)閣下明白香港發售股份不曾亦不會根據美國《證券法》登記；及(ii)閣下及閣下為其利益申請香港發售股份的人士均身處美國境外(定義見S規例)，又或屬S規例第902條第(h)(3)段所述的人士；
- 保證閣下提供的資料真實及準確；
- 同意接納所申請數目或根據申請分配予閣下較少數目的香港發售股份；
- 授權本公司將閣下的姓名 名稱列入本公司H股股東名冊，作為閣下獲分配任何香港發售股份的持有人，並授權本公司及 或其代理以普通郵遞方式按申請所示地址向閣下或聯名申請排名首位的申請人寄發任何H股股票及 或退款支票，郵誤風險由閣下承擔，除非閣下符合招股章程內「如何申請香港發售股份」章節中「親身領取」的條件領取H股股票及 或退款支票；
- 明白，根據香港聯交所發出的指引信HKEX-GL91-18，倘國際發售股份認購不足，香港發售股份超額認購，而不論倍數如何，最多22,010,000股發售股份可從國際發售重新分配至香港公開發售，因此香港公開發售項下可供認購股份總數將增至44,020,000股發售股份，約佔全球發售項下初步可供認購發售股份數目的20%(在任何超額配售權獲行使前)，而最終發售價必須定於招股章程所述的指示性發售價範圍的下限(即每股發售股份18.40港元)。有關重新分配的詳情載於招股章

如閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

程「全球發售的架構 — 香港公開發售 — 重新分配」一段；

- 聲明及表示此乃閣下為本身或閣下為其利益提出申請人士的利益提出及擬提出的唯一申請；
- 明白本公司及聯席全球協調人將依據閣下的聲明及陳述決定是否向閣下配發任何香港發售股份，閣下如作出虛假聲明，可能會被檢控；
- (如本申請為閣下本身的利益提出)保證閣下或作為閣下代理的任何人士或任何其他人士不曾亦不會為閣下的利益以白色或黃色申請表格或向香港結算或網上白表服勒 淨魚 平漸 畚燃 襪譚 錯籤 •

Personal Data

Personal Information Collection Statement

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and its H Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the “**Ordinance**”).

1. Reasons for the collection of your personal data

It is necessary for applicants and registered holders of securities to supply correct personal data to the Company or its agents and the H Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the H Share Registrar. Failure to supply the requested data may result in your application for securities being rejected, or in delay or the inability of the Company or its H Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of H Share certificate(s) and/or refund cheque(s) to which you are entitled.

It is important that securities holders inform the Company and the H Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the securities holders may be used, held, processed, and/or stored (by whatever means) for the following purposes:

- processing your application and refund cheque, where applicable, verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of securities’ holders including, where applicable, HKSCC Nominees;
- maintaining or updating the register of securities’ holders of the Company;
- verifying securities’ holders’ identities;
- establishing benefit entitlements of securities’ holders of the Company, such as dividends, rights issues, bonus issues, etc.;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities’ holder profiles;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the H Share Registrar to discharge their obligations to securities’ holders and/or regulators and/or any other purposes to which the securities’ holders may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and its H Share Registrar relating to the securities holders will be kept confidential but the Company and its H Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose, obtain or transfer (whether within or outside Hong Kong) the personal data to, from or with any of the following:

- the Company’s appointed agents such as financial advisers, receiving bankers and overseas principal share registrar;
- where applicants for securities request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the H Share Registrar in connection with their respective business operation;
- the Hong Kong Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the securities’ holders have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers, etc.

4. Retention of personal data

The Company and its H Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. Access to and correction of personal data

Securities holders have the right to ascertain whether the Company or the H Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the H Share Registrar have the right to charge a reasonable fee for the processing of such requests.

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the “Corporate Information” section of the Prospectus or as notified from time to time, for the attention of the company secretary, or our H Share Registrar for the attention of the privacy compliance officer.

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

個人資料

個人資料收集聲明

此項個人資料收集聲明是向香港發售股份的申請人和持有人說明有關本公司及其H股證券登記處有關個人資料和香港法例第486章《個人資料(私隱)條例》(「《條例》」)方面的政策和慣例。

1. 收集閣下個人資料的原因

證券申請人及登記持有人以本身名義申請證券或轉讓或受讓證券時或尋求H股證券登記處的服務時，必須向本公司或其代理人及H股證券登記處提供準確及可與公眾獲取的資料。

蝨

串